Gene · 3352
HTR1D: 5-hydroxytryptamine receptor 1D
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. HTR1D: 5-hydroxytryptamine receptor 1D. Genes, record 3352. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3352
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P28221 | 5-hydroxytryptamine receptor 1D | 377 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents32
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 35752 | P28221 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 35753 | P28221 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2002 | P28221 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2002 | P28221 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 391 | P28221 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 391 | P28221 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 298 | P28221 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 103362 | P28221 | Espacenet |
| US 10772934 B2 | 2020-09-15 | 1023 | P28221 | Espacenet |
| JP 2019158777 A | 2019-09-19 | 756 | P28221 | Espacenet |
1 to 10 of 32
See all 32 patentsDrugs28
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ALMOTRIPTAN | CHEMBL1505 | Serotonin 1d (5-HT1d) receptor agonist | AGONIST | ChEMBL |
| ALMOTRIPTAN MALATE | CHEMBL1200521 | Serotonin 1d (5-HT1d) receptor agonist | AGONIST | ChEMBL |
| AMISULPRIDE | CHEMBL243712 | Serotonin (5-HT) receptor antagonist | ANTAGONIST | ChEMBL |
| DEXFENFLURAMINE | CHEMBL248702 | Serotonin (5-HT) receptor agonist | AGONIST | ChEMBL |
| DEXFENFLURAMINE HYDROCHLORIDE | CHEMBL1887891 | Serotonin (5-HT) receptor agonist | AGONIST | ChEMBL |
| DIHYDROERGOTAMINE | CHEMBL1732 | Serotonin 1d (5-HT1d) receptor agonist | AGONIST | ChEMBL |
| DIHYDROERGOTAMINE MESYLATE | CHEMBL1200517 | Serotonin 1d (5-HT1d) receptor agonist | AGONIST | ChEMBL |
| DONITRIPTAN | CHEMBL1742428 | Serotonin 1d (5-HT1d) receptor agonist | AGONIST | ChEMBL |
| ELETRIPTAN | CHEMBL1510 | Serotonin 1d (5-HT1d) receptor agonist | AGONIST | ChEMBL |
| ELETRIPTAN HYDROBROMIDE | CHEMBL1201003 | Serotonin 1d (5-HT1d) receptor agonist | AGONIST | ChEMBL |
1 to 10 of 28
See all 28 drugsTrials214
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07555171 | FENFLURAMINE | ClinicalTrials.gov | ||
| NCT07503444 | FENFLURAMINE HYDROCHLORIDE | PHASE3 | ClinicalTrials.gov | |
| NCT07152184 | AMISULPRIDE | PHASE2 | ClinicalTrials.gov | |
| NCT07112365 | FENFLURAMINE | PHASE4 | ClinicalTrials.gov | |
| NCT07103694 | SUMATRIPTAN | ClinicalTrials.gov | ||
| NCT06887621 | AMISULPRIDE | PHASE2 | ClinicalTrials.gov | |
| NCT06868953 | SUMATRIPTAN | ClinicalTrials.gov | ||
| NCT06677229 | ELETRIPTAN HYDROBROMIDE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT06598449 | FENFLURAMINE | PHASE4 | ClinicalTrials.gov | |
| NCT06585540 | AMISULPRIDE | PHASE3 | ClinicalTrials.gov |
1 to 10 of 214
See all 214 trialsNIH grants552
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | HTR1D papers | Newest fiscal year |
|---|---|---|---|
| ZIAMH002793 | PET Radiopharmaceutical Sciences | 6 | 2025 |
| ZIACP010121 | Molecular Epidemiology Studies of Occupational and Environmental Exposures | 4 | 2025 |
| ZIAMH002795 | Translational Evaluation of PET Radiotracers | 4 | 2025 |
| R01MH112205 | Molecular Details of Psychoactive Drug Actions | 3 | 2025 |
| T32DE014318 | Craniofacial Oral-biology Student Training in Academic Research (COSTAR) | 2 | 2025 |
| ZIADA000522 | Preclinical medication development for stimulant use disorder | 2 | 2025 |
| I01CX001301 | Effects of ADT on motivation and emotion function in prostate cancer patients: longitudinal imaging and prediction | 1 | 2025 |
| P01CA019014 | Viral Oncogenesis, Latency, and Replication | 1 | 2025 |
| P20GM103427 | Nebraska Research Network in Functional Genomics | 1 | 2025 |
| P20GM103430 | Rhode Island IDeA Network of Biomedical Research Excellence | 1 | 2025 |
1 to 10 of 552Source NIH's project files
See all 552 nih grantsPapers1,118
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Antidepressant Vortioxetine Potently Inhibits Cell Growth in Cultured Human Glioblastoma Cells Expressing 5-HT1B Serotonin Receptors. | Cells | 2026 | 42587732 | PubTator, text mining | PubMed |
| A three-gene signature correlated with MAPK/ERK activation characterizes acquired resistance to EGFR-tyrosine kinase inhibitors in non-small cell lung cancer. | Oncol Lett | 2026 | 42516805 | PubTator, text mining | PubMed |
| Pharmaco-behavioral profiling identifies suppressors of autism gene-associated phenotypes in zebrafish. | Proc Natl Acad Sci U S A | 2026 | 41838920 | PubTator, text mining | PubMed |
| Neuroimmunological Mechanisms of Xiao-Yao-San Against Chronic Stress-Induced Colorectal Cancer: A Bioinformatics and Single-Cell Sequencing Study. | Cancer Manag Res | 2026 | 41798904 | PubTator, text mining | PubMed |
| Differential conservation analysis identifies residues defining constitutive internalization in beta-adrenergic receptors. | iScience | 2026 | 41797919 | PubTator, text mining | PubMed |
| Coronary Artery Spasm in Patients with Type 2 Diabetes Mellitus. | Life (Basel) | 2026 | 41752989 | PubTator, text mining | PubMed |
| Emotional Blunting in Hong Kong Patients with Major Depressive Disorder Treated with Vortioxetine: A Naturalistic Observational Study. | Biomedicines | 2026 | 41751169 | PubTator, text mining | PubMed |
| Acute psilocin increased cortical activity in rat. | Front Neurosci | 2026 | 41716660 | PubTator, text mining | PubMed |
| Management strategies for burning mouth syndrome: a comprehensive review. | J Oral Facial Pain Headache | 2026 | 41607318 | PubTator, text mining | PubMed |
| Decoding Non-Neuronal Mechanisms and Therapeutic Targets in Huntington's Disease Through Integrative Transcriptomics and Machine Learning. | J Mol Neurosci | 2026 | 41553597 | PubTator, text mining | PubMed |
1 to 10 of 1,118
See all 1,118 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3352
GET https://conductscience.org/api/genes/v1/3352/patents?page=2